Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts

Prostate

Volumn 69, Issue 16, 2009, Pages 1730-1743

  Schmidt, Lucy J ^a   Regan, Kevin M ^a   Anderson, S Keith ^a   Sun, Zhifu ^a   Ballman, Karla V ^a   Tindall, Donald J ^a,b  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Dutasteride; Prostate; Xenograft

Indexed keywords

ANDROGEN; DUTASTERIDE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT; UNINDEXED SEQUENCE; UPREGULATION;

ANDROGENS; ANIMALS; AZASTEROIDS; CELL DIVISION; CHOLESTENONE 5 ALPHA-REDUCTASE; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; ENZYME INHIBITORS; GENE EXPRESSION; MALE; MICE; MICE, INBRED BALB C; MICROARRAY ANALYSIS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 70350441994     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21022     Document Type: Article

References (20)

1. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M, Rittmaster R. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172(4 Pt 1):1314-1317. (Pubitemid 39249705)
2. Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R. Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007;28(6):763-769. (Pubitemid 47499254)
3. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004;58(2):130-144.
4. Schmidt LJ, Murillo H, Tindall DJ. Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. J Androl 2004;25(6):944-953. (Pubitemid 39425600)
5. Shao TC, Li H, Ittmann M, Cunningham GR. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. J Urol 2007;178(4 Pt 1): 1521-1527. (Pubitemid 47368383)
6. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006;12(13):4072-4079. (Pubitemid 44078095)
7. Schmidt LJ, Ballman KV, Tindall DJ. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. Prostate 2007;67(10):1111- 1120. (Pubitemid 46983340)
8. Ballman KV, Grill DE, Oberg AL, Therneau TM. Faster cyclic loess: Normalizing RNA arrays via linear models. Bioinformatics 2004;20(16):2778-2786.
9. Dudoit S, Yang YH, Callow MJ, Speed TP. Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments. Stat Sinica 2002;12(1):111-139.
10. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4(2):249-264.
11. Benjamini YaH Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc 1995;B(58):289-300.
12. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL. LuCaP 35: A new model of prostate cancer progression to androgen independence. Prostate 2003;55(4): 239-246. (Pubitemid 36618182)
13. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 2007;13(14):4130-4138.
14. Biancolella M, Valentini A, Minella D, Vecchione L, D'Amico F, Chillemi G, Gravina P, Bueno S, Prosperini G, Desideri A, Federici G, Bernardini S, Novelli G. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs 2007;25(5):491-497. (Pubitemid 47222914)
15. Heemers HV, Regan KM, Schmidt LJ, Anderson SK, Ballman KV, Tindall DJ. Androgen modulation of coregulator expression in prostate cancer cells. Mol Endocrinol 2009;23(4):572-583.
16. Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol 2008;22(3): 597-608.
17. Lyons LS, Burnstein KL. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol 2006;20(5): 1061-1072.
18. Tam SW, Theodoras AM, Pagano M. Kip1 degradation via the ubiquitin-proteasome pathway. Leukemia 1997;11(Suppl 3): 363-366. (Pubitemid 27313535)
19. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW. Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002;8(11):3419-3426. (Pubitemid 35340716)
20. Fina F, Muracciole X, Rocchi P, Nanni-Metellus I, Delfino C, Daniel L, Dussert C, Ouafik L, Martin PM. Molecular profile of androgen-independent prostate cancer xenograft LuCaP 23.1. J Steroid Biochem Mol Biol 2005;96(5):355-365. (Pubitemid 41384137)